a,b-methylene atp trisodium

α,β-Methylene ATP trisodium, a phosphonate analog of ATP, is a selective P2X agonist that induces enhanced contraction of UBSM. α,β-Methylene ATP trisodium inhibits P2X1 and P2X3, but is inactive against P2X2, 4 and 7.

(4R,4aS,5aS,6aR,6bS,7aR)-4-Hydroxy-3,6b-dimethyl-5-methylene-4,4a,5,5a,6,6a,7,7a-octahydrocyclopropa[2,3]indeno[5,6-b]furan-2(6bH)-one is a sesquiterpene lactone with a complex bicyclic structure [1].

α,β-Methylene ATP, a phosphonic analog of ATP, functions as a ligand for P2X3 and P2X7 receptors, and acts primarily as a selective agonist for P2X1 and P2X3 receptors, exhibiting minimal to no activity on P2X2, P2X4 through P2X7 receptors.

6-Me-ATP (N6-Methyl-ATP) trisodium, an N6-modified ATP derivative, exhibits high binding affinity for GSK3 and effectively serves as the phosphate group donor in GSK3β-catalyzed phosphorylation of its substrate peptide [1].

α,β-Methylene ATP dilithium, a phosphonic analog of ATP, serves as a ligand for P2X3 and P2X7 receptors. It is a potent agonist specifically targeting P2X1 and P2X3 receptors while exerting negligible activity on P2X2, P2X4, P2X5, P2X6, and P2X7 receptors.

Oxidized ATP trisodium salt (oATP) is a broad-spectrum P2 receptor inhibitor that irreversibly antagonizes P2X7R activation and inhibits CRP-induced NLRP3 inflammasome activation, making it useful in atherosclerosis research [1] [2].